Related Experiment Video

Updated: Jun 23, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population

Werner Koch1, Petra Hoppmann, Arne Pfeufer

  • 1Deutsches Herzzentrum München, Lazarettstrasse 36, 80636 München, Germany. wkoch@dhm.mhn.de

European Heart Journal
|September 7, 2006
PubMed

Insights

Toll-like receptor 4 (TLR4) gene polymorphisms, specifically 896A/G and 1196C/T, were not found to be associated with myocardial infarction (MI) in a large Caucasian study. These findings suggest TLR4 variants do not impact MI risk in this population.

Area of Science:

  • Immunology
  • Genetics
  • Cardiovascular Disease

Background:

  • Toll-like receptor 4 (TLR4) mediates immune responses and is implicated in atherosclerosis.
  • Specific single nucleotide polymorphisms (SNPs) in the TLR4 gene, 896A/G (rs4986790) and 1196C/T (rs4986791), are investigated for their potential role in cardiovascular disease.
  • Atherosclerosis involves plaque initiation, progression, and destabilization, processes where TLR4 may play a role.

Purpose of the Study:

  • To investigate the association between TLR4 gene polymorphisms (896A/G and 1196C/T) and their haplotypes with myocardial infarction (MI) risk.
  • To analyze potential sex-specific associations of these TLR4 polymorphisms and haplotypes with MI.
  • To assess the relationship between TLR4 genotypes, haplotypes, and diplotypes and MI in a large Caucasian cohort.

Main Methods:

  • Case-control study design.
  • Inclusion of 3657 MI patients and 1211 controls with angiographically normal coronary arteries.
  • Genotyping performed using TaqMan assays for 896A/G and 1196C/T TLR4 polymorphisms.

Main Results:

  • No significant differences in genotype distributions for 896A/G and 1196C/T polymorphisms were observed between MI patients and controls (P ≥ 0.30).
  • Haplotype frequencies and diplotype distributions did not differ significantly between the case and control groups (P ≥ 0.16 and P ≥ 0.12, respectively).
  • Separate analyses in men and women revealed no sex-related associations between specific TLR4 genotypes or haplotypes and MI (P ≥ 0.11).

Conclusions:

  • The studied 896A/G and 1196C/T polymorphisms of the TLR4 gene are not associated with myocardial infarction risk.
  • Haplotypes based on these TLR4 polymorphisms also show no significant association with MI in the investigated Caucasian population.
  • These findings do not support a role for these specific TLR4 genetic variations in the development of MI.
Abstract

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...